Literature DB >> 31594075

[CCI clinical practice guidelines: management of TIPS for portal hypertension (2019 edition)].

.   

Abstract

Portal hypertension(PH) is one of the main complications of cirrhosis.Transjugular intrahepatic portosystemic shunt(TIPS) is the percutaneous creation of a conduit from the hepatic vein to the portal vein that is used to manage consequences of PH (i.e., variceal bleeding and refractory ascites) and used as a bridging therapy to liver transplant for decompensated cirrhosis. The following Clinical Practice Guidelines (CPGs) presents profession associational recommendations of the Chinese College of Interventionalists(CCI) on TIPS for PH. The CPGs was written by more than 30 experts in the field of TIPS in China (including interventional radiologists, liver surgeons, hepatologists and gastroenterologist, et al.). The panel of experts, produced these CPGs using evidence from PubMed and Cochrane database searches and combined with relevant expert consensuses and high quality clinical researches in China providing up to date guidance on TIPS for PH with the only purpose of improving clinical practice.

Entities:  

Keywords:  Clinical practice guidelines; Liver cirrhosis; Portal hypertension; Refractory ascites; Transjugular intrahepatic portosystemic shunt; Variceal bleeding

Mesh:

Year:  2019        PMID: 31594075     DOI: 10.3760/cma.j.issn.1007-3418.2019.08.002

Source DB:  PubMed          Journal:  Zhonghua Gan Zang Bing Za Zhi        ISSN: 1007-3418


  2 in total

1.  Effects of transjugular intrahepatic portosystemic shunt using the Viatorr stent on hepatic reserve function in patients with cirrhosis.

Authors:  Xin Yao; Hao Zhou; Shan Huang; Shan-Hong Tang; Jian-Ping Qin
Journal:  World J Clin Cases       Date:  2021-03-06       Impact factor: 1.337

2.  Anticoagulation after transjugular intrahepatic portosystemic shunt for portal hypertension: A systematic review and meta analysis.

Authors:  Pan Jiao; Xu-Ying Chen; Hong-Yan Zheng; Jia Qin; Chao Li; Xiao-Lin Zhang
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.